Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
Superko
H Robert
HR
King
Spencer
S
D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D020022:Genetic Predisposition to Disease; D006040:Goals; D019983:Guideline Adherence; D019538:Health Care Surveys; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D016547:Kinesins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D018579:Patient Selection; D017035:Pravastatin / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012306:Risk
D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin; C526774:KIF6 protein, human; D016547:Kinesins; D017035:Pravastatin